ReviewCell biochemistry and function2026
PDE4DIP/Myomegalin as a Golgi-Centrosome Scaffold in Compartmentalized Signaling, Microtubule Organization, and Disease-Associated Pathway Remodeling.
Review in Cell biochemistry and function, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PDE4DIP/Myomegalin was originally identified as a Golgi- and centrosome-associated protein that interacts with phosphodiesterase 4D, but subsequent work has placed it within a broader network of organelle-associated signaling and cytoskeletal regulation. This review examines PDE4DIP/Myomegalin as a coiled-coil-rich scaffold linking compartmentalized cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling, Golgi-centrosome organization, microtubule architecture, and disease-associated pathway remodeling. At the centrosome, long PDE4D-binding myomegalin forms retain PDE4D3 and restrict local PKA activity, thereby influencing Hedgehog signaling. At the Golgi, AKAP9/AKAP450 provides a major scaffold, while selected myomegalin forms support Golgi-derived microtubule organization and endoplasmic reticulum-Golgi trafficking. In KRAS-mutant colorectal cancer models, PDE4DIP promotes tumor growth and MEK inhibitor resistance through Golgi-associated NF1/RAS pathway remodeling. In non-small cell lung cancer, PDE4DIP cooperates with AKAP9 to maintain Golgi localization and stability of PKA regulatory subunit II alpha; PDE4DIP loss activates PKA/cAMP response element-binding protein signaling and suppresses tumor growth. Cardiovascular studies link myomegalin isoform 4 to sarcomeric PKA signaling, co-occurring PDE4DIP and DES variants to conduction phenotypes, and PDE4DIP dysregulation to left ventricular noncompaction-associated cellular changes, although the evidence remains context dependent. Neurological and retinal disease associations remain largely exploratory. Recent work links a PDE4DIP-AKAP9 interaction to cytoskeletal integrity and RAS-ERK/AKT signaling in podocyte injury. Overall, PDE4DIP/Myomegalin is best understood as an organelle-associated organizer whose effects depend on the experimentally reported form, binding partners, and subcellular address rather than on a single linear pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.